The FDA approved Alkindi Sprinkle (hydrocortisone), on September 29, 2020, as a replacement therapy for adrenocortical Insufficiency (AI) in children under 17 years of age.Pediatric adrenocortical Insufficiency (AI) is a rare disease characterized by an inability to synthesize and release cortisol, and sometimes aldosterone causing abnormal sexual development in females, premature puberty, premature growth termination, and short stature.Alkindi Sprinkle is the first and only FDA-approved granular hydrocortisone formulation for the treatment of adrenocortical insufficiency specifically designed for use in children.Prior to Alkindi Sprinkle’s approval, caregivers had to cut or split higher strength hydrocortisone tablets to meet the lower dosing needs of children with adrenocortical insufficiency, which could result in inaccurate dosing.The drug comes with warnings about adrenal crisis, infections, growth retardation, Cushing’s syndrome, decrease in bone mineral density, and psychiatric, ophthalmic, and gastrointestinal adverse reactions.Eton Pharmaceuticals, Inc. (ETON) acquired the U.S. marketing rights to Alkindi Sprinkle from Diurnal Group plc (DNL) in March, 2020.Eton expects Alkindi Sprinkle to be commercially available this quarter.